about
Guidelines for the use and interpretation of assays for monitoring autophagyThe human homologue of Dictyostelium discoideum phg1A is expressed by human metastatic melanoma cellsMechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infectionHigh levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients.Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Metabolic Networks in CancerProton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cellsSurrogate markers as a guide to evaluate response to antiretroviral therapy.FasL and TRAIL induce epidermal apoptosis and skin ulceration upon exposure to Leishmania major.Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid TumorsAutophagy is a protective mechanism for human melanoma cells under acidic stress.Tumor acidity, chemoresistance and proton pump inhibitors.B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design.Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance.Acidic extracellular pH neutralizes the autophagy-inhibiting activity of chloroquine: implications for cancer therapies.A rationale for the use of proton pump inhibitors as antineoplastic agents.Proton channels and exchangers in cancer.The Role of Autophagy in the Maintenance of Stemness and Differentiation of Mesenchymal Stem Cells.Pathobiology and therapeutic implications of tumor acidosis.Therapeutic implications of tumor interstitial acidification.Clinical evaluation of an in-house reverse transcription-competitive PCR for quantitation of human immunodeficiency virus type 1 RNA in plasmaEradicating Quiescent Tumor Cells by Targeting Mitochondrial Bioenergetics.P-glycoprotein binds to ezrin at amino acid residues 149-242 in the FERM domain and plays a key role in the multidrug resistance of human osteosarcoma.pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity.The plant alkaloid voacamine induces apoptosis-independent autophagic cell death on both sensitive and multidrug resistant human osteosarcoma cells.Low human immunodeficiency virus type 1 (HIV-1) DNA burden as a major cause for failure to detect HIV-1 DNA in clinical specimens by PCR.Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species.Tumor acidosis enhances cytotoxic effects and autophagy inhibition by salinomycin on cancer cell lines and cancer stem cellsThe acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors.Proton dynamics in cancer.Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8-coinfected patients.Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions.Altered distribution of natural killer cell subsets identified by CD56, CD27 and CD70 in primary and chronic human immunodeficiency virus-1 infection.Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors.Evaluation of cell-free and cell-associated peripheral blood human immunodeficiency virus type 1 RNA response to antiretroviral therapy.Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment.Concordance between polymerase chain reaction and antibody detection in the diagnosis of human immunodeficiency virus type 1 infection.Human immunodeficiency virus-1 infection, homosexuality, and Kaposi-associated herpes-like DNA in peripheral blood mononuclear cells.Metabolism and microenvironment in cancer plasticity.Proton pump inhibitors may reduce tumour resistance.Effects of potent antiretroviral therapy on the immune activation marker soluble CD27 in patients infected with HIV-1 subtypes A-D.
P50
Q21996341-83068C9F-0F48-40AE-8778-C061BF870730Q28118773-F9CA5DE0-6CBF-4054-A58A-61CDDB1145BFQ28182419-21371482-F82A-406C-BB94-0A61474B4CD4Q33432819-E2C574CB-2AAE-444E-91E1-8DEA1A829FCDQ33869480-4CCACC46-7207-42E7-A21D-0CD534C59C4EQ34561771-70267D64-CE73-4A15-BA02-4A722C0235EAQ35060928-AC5F15C8-58B9-4DD1-A440-42C7EF13CB30Q35570373-0BB235D2-4622-4840-ADDF-D1E2F039FE3DQ35845149-C2F488E1-2395-4E68-AFDD-CC7EDEEF4FB6Q36216450-0DFC8A82-0BA8-4DA7-BF19-5556BFA4D98DQ36429624-CDBAC2DF-C676-4C4C-9271-2F6BC5D4EA27Q37047141-AD183BA7-DCE2-43B1-920E-51BA5212FD48Q37665338-75D1D396-5ABB-4B6E-A03F-C3352A251F02Q37699466-EA2D2D87-1A1E-4CBD-A4D4-BC6604AB8662Q37987589-5F788784-0000-4961-99E7-E48282A626A7Q38275646-798D5CF0-553F-4D9F-B21A-55BC0951CF58Q38970616-251BAAA3-687F-4A23-9272-A255E986ACF9Q39061437-D8B496FE-0E32-4C95-A06E-8D370F698B7EQ39131256-E7DD3948-50B7-4799-BC19-589A2B606F05Q39446249-A64DDFAA-23A1-435B-869F-BF77BCFAEF14Q39456813-99B15F95-8288-45E7-82E5-685A02E8129CQ39502697-A2CDA1F4-F595-4C24-90C9-C6F8E7AE0FAEQ39781678-DB513DA6-C77F-4A2B-8DB6-FBA81FFD720BQ39931975-393405F4-84BB-4B47-B416-950F99A98D04Q40006712-A883A8C8-B3F2-42E0-898F-523F59A4478DQ40124631-1A487FD9-99B5-4601-8268-7D819024EB75Q41667100-351B052A-38BF-4353-8607-5431EF4D3834Q41779445-E45BC987-B006-4BE0-A11B-6DB4C2622A64Q42730234-7B0F7310-B209-4025-89FF-F77331500E90Q43424239-B80A120D-D6C3-4BAF-99D5-9E22117BA7A3Q43480181-B0026B1E-BE73-46E9-A42D-EF39223829EEQ45401936-CC92544F-D994-4B86-B1DB-1D127B8D9095Q45748748-6301CA8E-052D-4DA2-A2FD-51C60A50BB18Q45751982-026532DB-2F21-4F9B-B7E2-F2B2D4843C04Q45765110-CDDFF12D-1D9D-4CD5-BF8F-8E89CA6C3504Q45770324-5A1B2832-8DA7-4D3A-92E1-0EC55CF9912EQ45771336-18A1972D-EA38-4923-AB25-B2A36B744621Q45908708-D642A8D0-BAAE-4AF4-B746-A0097248EEC6Q46548498-8287B47A-0F31-465D-AB0C-84E0442A4E0BQ47236316-35AC082A-A479-451F-875F-A105BB16F75A
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Angelo De Milito
@ast
Angelo De Milito
@en
Angelo De Milito
@es
Angelo De Milito
@nl
type
label
Angelo De Milito
@ast
Angelo De Milito
@en
Angelo De Milito
@es
Angelo De Milito
@nl
prefLabel
Angelo De Milito
@ast
Angelo De Milito
@en
Angelo De Milito
@es
Angelo De Milito
@nl
P106
P21
P31
P496
0000-0003-2591-2914